NEW TREATMENT FOR CHRONIC LOW BACK PAIN APPROVED BY HEALTH CANADA

TORONTO, April 29 /CNW/ - Eli Lilly Canada announced today that Health Canada has approved Cymbalta® (duloxetine HCl) for the management of chronic low back pain (CLBP).  The recommended dose is 60 mg once daily.

The approval is based on the results of two randomized, double-blind, 12-13 week, placebo-controlled studies in 637 adult patients with a clinical diagnosis of CLBP with pain present on most days for at least 6 months and no sign of radiculopathy or spinal stenosis.1 The primary efficacy endpoint in both studies was a reduction in pain severity as measured by the Brief Pain Inventory (PBI) 24-hour average pain rating on the 11-point Likert scale (0 = no pain; 10 = worst possible pain). In both studies, patients taking Cymbalta 60 mg once daily experienced significantly greater pain reduction compared to placebo.  In addition, some patients reported pain reduction as early as one week into the trial after starting the 60 mg dose, which continued throughout the study.

Cymbalta has been evaluated for safety in 698 patients with CLBP. The most common side effects reported in the two studies included nausea, insomnia, somnolence, constipation, dry mouth, fatigue and dizziness.1

About Low Back Pain2
Most adults experience low back pain at some point in their lives. Men and women are equally affected. Low back pain occurs most often between ages 30 and 50, due in part to the aging process but also as a result of sedentary life styles with too little (sometimes punctuated by too much) exercise. Fortunately, most occurrences go away within a few days. Others take much longer to resolve or lead to more serious conditions.

What Causes CLBP?2
Chronic back pain is measured by duration — pain that persists for more than three months is considered chronic. It is often progressive and the cause can be difficult to determine. Low back pain may reflect nerve or muscle irritation or bone lesions. Most low back pain follows injury or trauma to the back, but pain may also be caused by degenerative conditions such as arthritis or disc disease, osteoporosis or other bone diseases, or rarely by infections, tumours, or congenital abnormalities in the spine.

About Cymbalta
Cymbalta is a potent and balanced serotonin and norepinephrine reuptake inhibitor (SNRI), which targets two chemical messengers in the brain believed to play a role in sensitivity to pain - serotonin and norepinephrine. While the mechanism of action of duloxetine in humans is not fully known, scientists believe its effect on pain perception is due to increasing the activity of serotonin and norepinephrine in the central nervous system.

Cymbalta is now indicated in Canada for three distinct pain conditions: CLBP, neuropathic pain associated with diabetic peripheral neuropathy and fibromyalgia.  It is also indicated in Canada for the symptomatic relief of major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Duloxetine is contraindicated in patients who are allergic to it, who have liver disease resulting in hepatic impairment, who are taking a monoamine oxidase inhibitor (MAOI) including linezolid and methylene blue, thiorazidine, potent CYP1A2 inhibitors (e.g. fluvoxamine), and some guinolone antibiotics (e.g. ciprofloxacin or enoxacine), who have uncontrolled narrow glaucoma, or who have severe kidney disease.

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs.  Eli Lilly Canada, headquartered in Toronto, Ontario, employs close to 500 people across the country.  Additional information about Eli Lilly Canada can be found at www.lilly.ca.

® Registered trademark owned by Eli Lilly and Company; used under license.

References:
__________________________

1 Cymbalta product monograph. Eli Lilly Canada. 2011.
2  National Institutes of Health. Low Back Fain Fact Sheet.  Available at: http://www.ninds.nih.gov/disorders/backpain/detail_backpain.htm  Last updated February 18, 2011. Accessed April 14, 2011.


 

 

 

 

SOURCE Eli Lilly Canada Inc.

For further information:

Julie Holroyde
Cohn & Wolfe
(416) 924-5700 ext. 4048
julie.holroyde@cohnwolfe.ca

Profil de l'entreprise

Eli Lilly Canada Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.